BIM
ALXN

BlackRock Investment Management’s Alexion Pharmaceuticals ALXN Stock Holding History

BlackRock Investment Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$282M Buy
2,305,045
+61,368
+3% +$7.51M 0.33% 53
2016
Q3 		$275M Buy
2,243,677
+1,433,769
+177% +$185M 0.34% 54
2016
Q2 		$94.6M Buy
809,908
+139,409
+21% +$19.8M 0.12% 175
2016
Q1 		$93.3M Sell
670,499
-39,314
-6% -$5.77M 0.12% 173
2015
Q4 		$135M Sell
709,813
-6,303
-0.9% -$1.1M 0.17% 119
2015
Q3 		$112M Buy
716,116
+23,907
+3% +$4.36M 0.15% 139
2015
Q2 		$125M Buy
692,209
+222,142
+47% +$38.3M 0.16% 133
2015
Q1 		$81.5M Buy
470,067
+5,668
+1% +$1.03M 0.11% 195
2014
Q4 		$85.9M Sell
464,399
-515
-0.1% -$95.4K 0.11% 183
2014
Q3 		$77.1M Sell
464,914
-2,901
-0.6% -$476K 0.11% 184
2014
Q2 		$73.1M Buy
467,815
+92,500
+25% +$14.6M 0.1% 207
2014
Q1 		$57.1M Buy
375,315
+33,319
+10% +$5.3M 0.08% 231
2013
Q4 		$45.4M Sell
341,996
-12,624
-4% -$1.51M 0.07% 265
2013
Q3 		$41.2M Sell
354,620
-133,217
-27% -$14.6M 0.07% 265
2013
Q2 		$45M Buy
+487,837
New +$47M 0.08% 224

Other funds holding ALXN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

BlackRock Investment Management's ALXN Position: Q4 2016 in Review

BlackRock Investment Management increased its Alexion Pharmaceuticals (ALXN) stake by 2.7% in Q4 2016, buying an estimated $7.51M and bringing the position to 2,305,045 shares worth $282M. The position accounts for 0.33% of the portfolio, ranked #53.

BlackRock Investment Management first reported a position in ALXN in Q2 2013 and has held it in 15 quarters since. 549 funds tracked by Wall St. Rank hold ALXN as of Q4 2016.

  • BlackRock Investment Management held 2,305,045 shares of Alexion Pharmaceuticals worth $282M as of Q4 2016.
  • BlackRock Investment Management bought 61,368 Alexion Pharmaceuticals shares in Q4 2016, an estimated $7.51M.
  • Alexion Pharmaceuticals made up 0.33% of BlackRock Investment Management's portfolio in Q4 2016, its #53 holding.
  • BlackRock Investment Management first reported a position in Alexion Pharmaceuticals in Q2 2013 and has held it in 15 quarters since.
  • 549 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2016.

Based on BlackRock Investment Management's 13F filing for Q4 2016, filed 10 Feb 2017.